Cost-effectiveness of cardiac rehabilitation program delivery models in patients at varying cardiac risk, reason for referral, and sex

European Journal of Preventive Cardiology

Volumn 15, Issue 3, 2008, Pages 347-353

  Papadakis, Sophia ^a   Reid, Robert D ^a   Coyle, Doug ^b   Beaton, Louise ^a   Angus, Douglas ^b   Oldridge, Neil ^c  

^a Rehabilitation Centre   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

cardiac rehabilitation; cost utility; health economics; secondary prevention

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; ECONOMICS; EXERCISE; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PATIENT REFERRAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REHABILITATION; RISK FACTOR; SEX DIFFERENCE; TIME; CARDIOVASCULAR RISK; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; HEALTH CARE DELIVERY; HEALTH PROGRAM; HEART REHABILITATION; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PRIORITY JOURNAL;

ADULT; AGED; CORONARY ARTERY DISEASE; COST-BENEFIT ANALYSIS; DIRECT SERVICE COSTS; EXERCISE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; REFERRAL AND CONSULTATION; REHABILITATION; RISK FACTORS; SEX FACTORS; TIME FACTORS;

EID: 56149104398     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e3282f5ffab     Document Type: Article

References (23)

1. Stone JA, Cyr C, Friesen M, Kennedy-Symonds H, Stene R, Smilovitch M. Canadian guidelines for cardiac rehabilitation and cardiovascular and atherosclerotic heart disease prevention: a summary. Can J Cardiol 2001; 17: 3B–30B.
2. Giannuzzi P, Saner H, Bjornstad H, Fioretti P, Mendes M, Cohen-Solal A et al. Secondary prevention through cardiac rehabilitation. Eur Heart J 2003; 24: 1273–1278.
3. Leon AS, Franklin BA, Costa F, Balady GJ, Berra KA, Stewart KJ et al. Cardiac rehabilitation and secondary prevention of coronary heart disease. Circulation 2005; 111: 369–376.
4. Taylor R, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 2004; 116: 682–692.
5. Brubaker PH, Warner JG, Rejeski WJ, Edwards DG, Matrazzo BA, Ribisl PM et al. Comparison of standard – and extended – length participation in cardiac rehabilitation on body composition, functional capacity, and blood lipids. Am J Cardiol 1996; 78: 769–773.
6. Reid R, Dafoe W, Morrin L, Mayhew A, Papadakis S, Beaton L et al. Impact of program duration and contact frequency on efficacy and cost of cardiac rehabilitation: results of a randomized trial. Am Heart J 2005; 149: 862–868.
7. Oldridge N, Furlong W, Feeny D, Torrance G, Guyatt G, Crowe J, Jones N. Economic evaluation of cardiac rehabilitation soon after acute myocardial infarction. Am J Cardiol 1993; 72: 154–161.
8. Yu C, Lau C, Chau J, McGhee S, Kong SL, Cheung BM, Li L.S., A short course of cardiac rehabilitation program is highly cost-effective in improving long-term quality of life in patients with recent myocardial infarction or percutaneous coronary intervention. Arch Phys Med Rehabil 2004; 85: 1915–1922.
9. Briffa TG, Eckermann SD, Griffiths AD, Harris PJ, Heath MR, Freedman SB et al. Cost-effectiveness of rehabilitation after an acute coronary event: a randomised controlled trial. MJA 2005; 183: 450–455.
10. Papadakis S, Oldridge N, Coyle D, Mayhew A, Reid RD, Beaton L et al. Economic evaluation of cardiac rehabilitation: a systematic review. Eur J Cardiovasc Prev Rehabil 2005; 12: 513–520.
11. Lowensteyn I, Coupal L, Zowall H, Grover SA. The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease. J Cardiopulm Rehabil 2000; 20: 147–155.
12. Prochaska J, DiClemente C, Norcross J. In search of how people change: applications to addictive behaviours. Am Psychol 1992; 9: 1104–1114.
13. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1253–1258.
14. Glennie J, Torrance G, Baladi J, Berka C, Hubbard E, Menon D et al. The revised Canadian guidelines for the economic evaluation of pharmaceuticals. Pharmacoeconomics 1999; 15: 459–468.
15. Joint Policy and Planning Committee (JPPC). Cardiac funding working group final report: a programmatic approach to funding cardiac and cardiology procedures. 1997: RD4–RD9.
16. OHIP Billing Schedule. Ontario Ministry of Health, 2002.
17. United States Government. Economic report of the President, 2005.
18. Bennett KJ, Torrance GW. Measuring health state preferences and utilities: Rating scale, time trade-off, and standard gamble techniques. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven; 1996. pp. 253–265.
19. Drummond M, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programs, 2nd Ed. Oxford: Oxford University Press; 1997.
20. Efron B, Gong G. A leisurely look at the bootstrap, the jacknife, and cross-validation. Am Stat 1983; 37: 36–48.
21. Lothgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 2000; 9: 623–630.
22. Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, Greenberg D, Neumann PJ. Bias in published cost effectiveness studies: systematic review. BMJ 2006; 332: 699–703.
23. Scott L, Ben-Or K, Allen J. Why are women missing from outpatient cardiac rehabilitation programs? J Womens Health 2002; 11: 773–791.